Matthew H. Kulke

机构：Boston Medical Center · ORCID：0000-0001-8556-3977

发表论文 419 篇 · 总被引 28823 次 · h-index 82

代表论文

• PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer (2023 · Molecular Cancer · 被引 2080)
• Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors (2024 · New England Journal of Medicine · 被引 151)
• Intertumoral lineage diversity and immunosuppressive transcriptional programs in well-differentiated gastroenteropancreatic neuroendocrine tumors (2023 · Science Advances · 被引 34)
• LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET) (2023 · Annals of Oncology · 被引 28)
• Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma (2023 · Lung Cancer · 被引 20)
• Diagnosis and Management of Parathyroid Carcinoma (2024 · Clinical Pharmacology & Therapeutics · 被引 8)